Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

Health Net Federal Services Receives Contract Extension Of Up To Three Additional One-year Option Periods To Continue Providing Tricare Services - Yahoo Finance

http://alexsimring.blogspot.com/ Health Net Federal Services processes authorizations for health care on behalf of VA for veterans to receive care from authorized community providers, schedules appointments, manages receipt of all required medical documentation for care, and processes claims for payment. For information about Health Net Federal Services, please visit www.hnfs.com . About Health Net Health Net, Inc. ( HNT ) is a publicly traded managed care organization that delivers managed health care services through health plans and government-sponsored managed care plans. Its mission is to help people be healthy, secure and comfortable. Health Net provides and administers health benefits to approximately 6.0million individuals across the country through group, individual, Medicare (including the Medicare prescription drug benefit commonly referred to as Part D), Medicaid, dual eligible, U.S. Department of Defense, including TRICARE, and U.S. Department of Veterans Affairs programs.
Health Net Federal Services Receives Contract Extension of up to Three Additional One-Year Option Periods to Continue Providing TRICARE Services - Yahoo Finance

Health Care Sector Update for 03/27/2015: CNAT,BMRN,OHRP - NASDAQ.com

In company news, Conatus Pharmaceuticals ( CNAT ) extended gains Friday after the biotech company said Thursday that its emricasan drug candidate met its primary goal of reducing three biomarkers signaling liver damage during Phase II testing in patients with nonalcoholic fatty liver disease. The double-blind, placebo-controlled trial enrolled 38 patients receiving either 25 milligrams of emricasan or a placebo twice daily. According to the company, 30% of the patients in emricasan arm demonstrated declines in the three enzymes compared with just a 4% drop in the placebo arm. The drug also was safe and well tolerated during the latest trial, with no dose-limiting toxicities and no drug-related serious adverse events observed. CNAT plans to present detailed trial results at the International Liver Congress beginning April 22 in Vienna, Austria. CNAT shares were up more than 12% at $7.60 each this afternoon, advancing to a session high of $7.76 a share. The stock has traded within a 52-week range of $5.06 to $11.74 a share, having dropped more than 29% over the past 12 month prior to today's rally. In other sector news, (+) BMRN, (+11.9%) Deutsche Bank raises price target by nearly 56% from prior view to $140 a share while reiterating a Buy rating for the stock. (-) OHRP, (-66.4%) OHR-102 drug candidate fails to meet primary endpoint of reducing the number of injections of a previously approved drug used to treat "wet" aged-related macular degeneration during Phase II testing. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. Copyright (C) 2014 MTNewswires.com.

Don't be the product, buy the product!